Effect of surgical resection of metastatic disease on immune tolerance to cancer. How a systemic disease could be controlled by a local therapy

Clinical and Translational Oncology

Volumn 9, Issue 9, 2007, Pages 571-577

  Gonzalez H D ^a   Figueras, J ^a  

^a HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Immune tolerance; Liver surgery; Metastases; Tregulatory cells

Indexed keywords

BASILIXIMAB; CHEMOKINE RECEPTOR CCR4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; MONOCLONAL ANTIBODY; OXALIPLATIN; PEPTIDE VACCINE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; CYTOKINE RELEASE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; DRUG TREATMENT FAILURE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER METASTASIS; LOW DRUG DOSE; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; MICROMETASTASIS; MONOTHERAPY; NONHUMAN; POSTOPERATIVE COMPLICATION; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; SURGICAL TECHNIQUE; SYSTEMIC DISEASE; TREATMENT RESPONSE; TUMOR IMMUNITY; COLORECTAL TUMOR; IMMUNOLOGY; IMMUNOTHERAPY; LIVER TUMOR; LYMPHOCYTE; METASTASIS; PATHOLOGY;

COLORECTAL NEOPLASMS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; LIVER NEOPLASMS; LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 38449108086     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0105-5     Document Type: Review

References (47)

1. Wagner J, Adson M, Van Heerden J et al (1984) The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 199:502-504
2. Weber J, Bachelier P, Oussoultzoglou E et al (2003) Simultaneous resection of colorectal primary and synchronous liver metastases. Br J Surg 90:956-962
3. Figueras J, Valls C, Rafecas A et al (2001) Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 88:980-985
4. Poston G, Adam R, Alberts S et al (2005) Oncosurge: A strategy for improving resectability with curative intent in mestastatic colorectal cancer. J Clin Oncol 23:7125-7134
5. Figueras J, Torras J, Valls C et al (2007) Surgical resection of colorectal liver metastases in patients with expanded indications. A single-center experience with 501 patients. Dis Colon Rectum 50:478-488
6. Bismuth E, Adam R, Levi F et al (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509-520
7. Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy. A model to predict longterm survival. Ann Surg 240:644-657
8. Campi G, Crosti M, Consogno G et al (2003) CD4+ T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. Cancer Res 63:8481-8486
9. Schmitt E, Parcellier A, Ghiringhelli F et al (2004) Increased immunogenicity of colon cancer cells by selective depletion of cytochrome C. Cancer Res 64:2705-2711
10. Banerjea A, Bustin S, Dorudi S (2005) The immunogenicity of colorectal cancer with high-degree microsatellite instability. World J Surg Oncol 3:26
11. Shunyakov L, Ryan C, Sahasrabude D et al (2004) The influence of host response in colorectal cancer prognosis. Clin Colorectal Cancer 4:38-45
12. Jass J, Love S, Northover J (1987) A new prognostic classification of rectal cancer. Lancet 1:1303-1306
13. Naito Y, Saito K, Shiba K et al (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58:3491-3494
14. Evans C, Dalgleish A, Kumar D (2006) Immune suppression and colorectal cancer. Aliment Pharmacol Ther 8:1163-1177
15. Hensler T, Hecker H, Heeg K et al (1997) Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect Immun 65:2283-2291
16. Stalder M, Birsan T, Hausen B et al (2005) Immunosuppressive effects of surgery assessed by flow cytometry in nonhuman primates after nephrectomy. Transpl Intern 18:1158-1165
17. Weighardt H, Heidecke C, Emmanuilidis K et al (2000) Sepsis after major visceral surgery is associated with sustained and interferon-gamma-resistant defects of monocyte cytokine production. Surgery 127:309-315
18. Heidecke C, Weighardt H, Hensler T et al (2000) Immune paralysis of T-lymphocytes and monocytes in postoperative abdominal sepsis. Correlation of immune function with survival. Chirurg 71:159-165
19. O'sullivan S, Lederer J, Horgan A et al (1995) Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann Surg 222:482-490
20. Spolarics Z, Siddiqi M, Siegel J et al (2003) Depressed interleukin-12-producing activity by monocytes correlates with adverse clinical course and a shift toward Th2-type lymphocyte pattern in severely injured male trauma patients. Crit Care Med 31:1722-1729
21. Lyons A, Kelly J, Rodrick M et al (1997) Major injury induces increased production of interleukin-10 by cells of the immune system with a negative impact on resistance to infection. Ann Surg 226:450-458; discussion 458-460
22. Lyons A, Goebel A, Mannick J et al (1999) Protective effects of early interleukin-10 antagonism on injury-induced immune dysfunction. Arch Surg 134:1317-1323, discussion 1324
23. Kelly JL, Lyons A, Soberg C et al (1997) Anti-interleukin-10 antibody restores burn-induced defects in T cell function. Surgery 122:146-152
24. Kawaida H, Kono K, Takahashi A et al (2005) Distribution of CD4+CD25+ high regulatory T cells in tumor-draining lymph nodes in patients with gastric cancer. J Surg Res 124:151-157
25. Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295-307
26. Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: A common basis between tumor immunity and autoimmunity. J Immunol 163:5211-5218
27. Casares N, Arribillaga L, Sarobe P et al (2003) CD4+/CD25+ regulatory cells inhibit activation of tumour-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumour immunity elicited by peptide vaccination. J Immunol 171:5931-5939
28. Woo E, Chu Ch, Goletz T et al (2001) Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late stage ovarian cancer. Cancer Res 61:4766-4772
29. Okita R, Saeki T, Takashima S et al (2005) CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep 14:1269-1273
30. Ko K, Yamazaki S, Nakamura K et al (2005) Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating FoxP3CD25+CD4+ regulatory T cells. J Exp Med 202:885-891
31. Curiel T, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949
32. Kobayashi N, Hiraoka N, Yamagami W et al (2007) FOXP+regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 13:902-911
33. Yang X, Yamagiwa S, Ichida T et al (2006) Increase of CD4+CD25+ regulatory T cells in the liver of patients with hepatocellular carcinoma. J Hepatol 45:254-262
34. Unitt E, Rushbrook S, Marshall A et al (2005) Compromised lymphocytes infiltrate hepatocellular carcinoma: The role of T-regulatory cells. Hepatology 41:722-730
35. Shevach E (2004) Fatal attraction: Tumors beckon regulatory T cells. Nat Med 10:900-901
36. Liyanage U, Goedegebuure P, Moore T et al (2006) Increased prevalence of regulatory T cells (Tregs) is induced by pancreas adenocarcinoma. J Immunother 29:416-424
37. von Boehmer H (2003) Dynamics of suppressor T cells: In vivo veritas. J Exp Med 198:845-849
38. Kilinc M, Aulakh K, Nair R et al (2006) Reversing tumor immune suppression with intratumoral IL-12: Activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD+ T effectors. J Immunol 177:6962-6973
39. Correale P, Cusi M, Tsang K et al (2005) Chemo-immunotherapy of metastatic colorectal carcinoma with Gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2, induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 23:8950-8958
40. Jewell A (2005) Is the liver an important site for the development of immune tolerance to tumours? Med Hypotheses 64:751-754
41. Bowen D, Zen M, Holz L et al (2004) The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. J Clin Invest 114:701-712
42. Bowen D, McCaughan G, Bertolino P (2005) Intrahepatic immunity: A tale of two sites? Trends Immunol 26:512-517
43. Bertolino P, McCaughan G, Bowen D (2002) Role of primary intrahepatic T cell activation in the "liver tolerance effect". Immunol Cell Biol 80:84-92
44. Yoshimura N, Matsui S, Hamashima T et al (1990) The effects of perioperative portal venous inoculation with donor lymphocytes on renal allograft survival in the rat. Specific prolongation of donor grafts and suppressor factor in the serum. Transplantation 49:167-171
45. Katz S, Pillarisetty V, Bleier J et al (2004) Liver sinusoidal endothelial cells are insufficient to activate T cells. J Immunol 173:230-235
46. Sasada T, Kimura M, Yoshida Y et al (2003) CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: Possible involvement of regulatory T cells in disease progression. Cancer 98:1089-1099
47. Ichihara F, Kono K, Takahashi A et al (2003) Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9:4404-4408